Effect of chronic rosiglitazone, metformin and glyburide treatment on β-cell mass, function and insulin sensitivity in mZDF rats

Diabetes, Obesity and Metabolism

Volumn 10, Issue 9, 2008, Pages 780-790

  Atkinson, L L ^a   McDonald Dyck, C ^a   Benkoczi, C ^a   Finegood, Diane T ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

B cell death; B cell mass dynamics; B cell replication; Insulin resistance; Mathematical model

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL FUNCTION; CELL SIZE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MATHEMATICAL MODEL; MORPHOMETRICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; QUANTITATIVE ANALYSIS; RAT; TREATMENT DURATION; ZUCKER DIABETIC FATTY RAT;

EID: 50249165923     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00811.x     Document Type: Article

References (33)

1. Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108 (Suppl. 6a): 2S-8S.
2. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4: 110-125.
3. Clark A, Wells CA, Buley ID et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9: 151-159.
4. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85-96.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
6. Yoon KH, Ko SH, Cho JH et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
7. Pick A, Clark J, Kubstrup C et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-364.
8. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
9. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000; 2: 363-372.
10. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas: Estimation with a simple mathematical model. Diabetes 1995; 44: 249-256.
11. Donath MY, Ehses JA, Maedler K et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54 (Suppl. 2): S108-S113.
12. UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995; 44: 1249-1258.
13. Bar-On H, Ben-Sasson R, Ziv E, Arar N, Shafrir E. Irreversibility of nutritionally induced NIDDM in Psammomys obesus is related to beta-cell apoptosis. Pancreas 1999; 18: 259-265.
14. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265-281.
15. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005; 5: 349-363.
16. Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes. Evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 3794-3800.
17. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
18. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/ db mice. Am J Physiol Endocrinol Metab 2005; 288: E510-E518.
19. 2+ concentration. J Biol Chem 1998; 273: 33501-33507.
20. 2+ influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000; 271: 422-428.
21. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
22. Del Guerra S, Marselli L, Lupi R et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 2005; 19: 60-64.
23. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
24. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-5541.
25. Antico A. Morphometry in skin-test methodological studies - validation of point-counting technique for precise area determination. Allerg Immunol (Paris) 2004; 36: 219-224.
26. Topp B, Promislow K, deVries G, Miura RM, Finegood DT. A model of beta-cell mass, insulin, and glucose kinetics: Pathways to diabetes. J Theor Biol 2000; 206: 604-619.
27. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism 2007; 56: 24-29.
28. Tyrberg B, Eizirick DL, Hellerstrom C, Pipeleers DG, Andersson A. Human pancreatic beta-cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. Endocrinology 1996; 137: 5694-5699.
29. Chung BH, Li C, Sun BK et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005; 5: 1856-1867.
30. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90: 6678-6686.
31. Lupi R, Del Guerra S, Marselli L et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: Evidence for a role of PPARγ 2 in the modulation of insulin secretion. Am J Physiol 2004; 286: E560-E567.
32. Topp BG, Finegood DT. Estimation of insulin sensitivity from fasting glucose and insulin levels: Glucose is irrelevant except when insulin is low. Diabetes 2001; 50 (Suppl. 2): A523.
33. Topp BG, McArthur MD, Finegood DT. Metabolic adaptations to chronic glucose infusion in rats. Diabetologia 2004; 47: 1602-1610.